<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321554</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-G000-303</org_study_id>
    <nct_id>NCT01321554</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)</brief_title>
  <acronym>SELECT</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare
      the progression free survival of participants with 131 I -refractory DTC and radiographic
      evidence of disease progression within the prior 12 months, treated with lenvatinib 24 mg by
      continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a
      Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind
      treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment
      Period and a follow-up period).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization Phase: Participants will receive blinded study drug (lenvatinib/placebo) in 2:1
      ratio until documentation of disease progression (confirmed by independent imaging review),
      development of unacceptable toxicity, or withdrawal of consent. After having completed the
      primary analysis, subjects treated with lenvatinib who have not experienced disease
      progression may request to continue open label lenvatinib at the same dose, according to the
      clinical judgment of the investigator. Participants who discontinue treatment for any reason
      other than disease progression will be followed in the Randomization Phase until disease
      progression or start of another anticancer treatment; these participants then enter the
      Extension Phase for survival follow-up. Extension Phase: Participants in the placebo arm who
      have disease progression confirmed by IIR could request to enter the OOL Lenvatinib Treatment
      Period and receive lenvatinib treatment. Participants will receive lenvatinib treatment until
      disease progression (investigator's assessment), development of intolerable toxicity, or
      withdrawal of consent. Participants who had disease progression during the Randomization
      Phase and did not enter the OOL Lenvatinib Treatment Period and all participants who
      discontinued lenvatinib treatment in the OOL Lenvatinib Treatment Period will enter the
      follow-up period. Participants will be followed for survival, and all anticancer treatments
      will be recorded until the time of death.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 17, 2011</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years</time_frame>
    <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded independent imaging review (IIR) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years</time_frame>
    <description>ORR, defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by MRI/CT scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years</time_frame>
    <description>Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 6 Day 1</time_frame>
    <description>AUC was used to determine the total exposure of lenvatinib in blood plasma. From each participant, a total of up to 12 blood samples were collected at the following specified time points: predose, 0.5 to 4 hours postdose, and 6 to 10 hours postdose on Cycle 1/Day 1 and Cycle 1/Day 15; predose and 2 to 12 hours postdose on Cycle 2/Day 1; and predose only on Day 1 of Cycles 3 to 6. The samples were analyzed for the concentration of lenvatinib using validated analytical methods. Population PK model and observed concentration data were used to derive model-predicted lenvatinib PK parameters and lenvatinib exposure (AUC) based on the 24 mg starting dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Lenvatinib (Randomization Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Randomization Phase)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.</description>
    <arm_group_label>Lenvatinib (Randomization Phase)</arm_group_label>
    <arm_group_label>Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)</arm_group_label>
    <other_name>Lenvatinib (Lenvima, E7080)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.</description>
    <arm_group_label>Placebo (Randomization Phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.</description>
    <arm_group_label>Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)</arm_group_label>
    <other_name>Lenvatinib (Lenvima, E7080)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or cytologically confirmed diagnosis of one of the following DTC
             subtypes: Papillary thyroid cancer (PTC) or follicular thyroid cancer (FTC).

          2. Measurable disease according to (RECIST 1.1) and confirmed by central radiographic
             review.

          3. 131 I-refractory/resistant disease.

          4. Evidence of disease progression within 12 months prior to signing informed consent (+1
             month screening window).

          5. Prior treatment with 0 or 1 vascular endothelial growth-factor (VEGF) or vascular
             endothelial growth-factor receptors (VEGFR) targeted therapy.

          6. Adequate renal, liver, bone marrow, and blood coagulation function, as defined in the
             protocol.

        Exclusion criteria:

          1. Anaplastic or medullary carcinoma of the thyroid

          2. 2 or more prior VEGF/ VEGFR-targeted therapies

          3. Received any anticancer treatment within 21 days or any investigational agent within
             30 days prior to the first dose of study drug.

        Inclusion criteria for OOL Lenvatinib Treatment Period :

        Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period
        if the met the following criteria:

          1. Placebo-treated participants in the Randomization Phase who had progressive disease
             (PD) confirmed by IIR, and who requested treatment with lenvatinib.

          2. Participants who continued to satisfy specified inclusion and exclusion criteria as
             presented in the study protocol.

          3. Participants with maximum interval between the day of confirmation of PD by IIR and
             Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period of less than or equal to 3
             months.

          4. No systemic anticancer treatment during the interval between the day of confirmation
             of PD by the IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eisa Inc</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Boston</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Boston</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>San Salvador de Jujuy</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Joinville</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Novo Hamburgo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 3</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Livorno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 3</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 4</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 5</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Monserrato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Viagrande</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 1</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 2</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 1</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 1</name>
      <address>
        <city>Fukui-city</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 1</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 1</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 3</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 3</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 4</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 5</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Pathumwan</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 3</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 2</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility 1</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <results_first_submitted>March 13, 2015</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2016</results_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 612 subjects were screened for entry into the study. Of these 612 subjects, 220 subjects were screening failures and 392 subjects were randomly assigned to receive either lenvatinib or placebo in a 2:1 ratio.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenvatinib (Randomization Phase)</title>
          <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Randomization Phase)</title>
          <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="P3">
          <title>Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)</title>
          <description>Placebo treated participants in the Randomization Phase who had progressive disease confirmed by IIR, and who requested treatment with lenvatinib</description>
        </group>
        <group group_id="P4">
          <title>Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)</title>
          <description>Placebo treated participants in the Randomization Phase who had progressive disease confirmed by IIR, and who requested treatment with lenvatinib. The starting dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The starting dose was lowered at the request of the Data Monitoring Committee to 20mg on 16 Feb 2013.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Ongoing at Data Cutoff</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Due to Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="216">Discontinued due to disease progression or treatment ongoing at data cut off (15 Nov 2013)</participants>
                <participants group_id="P2" count="127">Discontinued due to disease progression or treatment ongoing at data cut off (15 Nov 2013)</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant choice</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OOL Lenvatinib Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Ongoing at Data Cutoff</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Due to Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="54">Discontinued due to disease progression or treatment ongoing at data cut off (15 Nov 2013)</participants>
                <participants group_id="P4" count="25">Discontinued due to disease progression or treatment ongoing at data cut off (15 Nov 2013)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant choice</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenvatinib (Randomization Phase)</title>
          <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Randomization Phase)</title>
          <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="261"/>
            <count group_id="B2" value="131"/>
            <count group_id="B3" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="10.57"/>
                    <measurement group_id="B2" value="61.5" spread="10.09"/>
                    <measurement group_id="B3" value="61.9" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded independent imaging review (IIR) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.</description>
        <time_frame>Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years</time_frame>
        <population>Full Analysis Set (Intent-to-Treat Analysis Set) included all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib (Randomization Phase)</title>
            <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Randomization Phase)</title>
            <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded independent imaging review (IIR) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.</description>
          <population>Full Analysis Set (Intent-to-Treat Analysis Set) included all randomized subjects.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="15.1">The upper limit of the 95% confidence interval was not estimable because an insufficient number of participants reached the event at the final assessment time point.</measurement>
                    <measurement group_id="O2" value="3.6" lower_limit="2.2" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.21</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR, defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by MRI/CT scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.</description>
        <time_frame>Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib (Randomization Phase)</title>
            <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Randomization Phase)</title>
            <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR, defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by MRI/CT scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="59.0" upper_limit="70.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.</description>
        <time_frame>Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib (Randomization Phase)</title>
            <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Randomization Phase)</title>
            <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.</description>
          <population>Full Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="22.0">The median OS was not yet reached for either the lenvatinib or the placebo arm (including crossover participants) at data cutoff date.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="14.3">The median OS was not yet reached for either the lenvatinib or the placebo arm (including crossover participants) at data cutoff date.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve</title>
        <description>AUC was used to determine the total exposure of lenvatinib in blood plasma. From each participant, a total of up to 12 blood samples were collected at the following specified time points: predose, 0.5 to 4 hours postdose, and 6 to 10 hours postdose on Cycle 1/Day 1 and Cycle 1/Day 15; predose and 2 to 12 hours postdose on Cycle 2/Day 1; and predose only on Day 1 of Cycles 3 to 6. The samples were analyzed for the concentration of lenvatinib using validated analytical methods. Population PK model and observed concentration data were used to derive model-predicted lenvatinib PK parameters and lenvatinib exposure (AUC) based on the 24 mg starting dose.</description>
        <time_frame>Cycle 1 Day 1 through Cycle 6 Day 1</time_frame>
        <population>PK Analysis Set - All the subjects who received at least one dose of study drug and had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib (Randomization Phase)</title>
            <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve</title>
          <description>AUC was used to determine the total exposure of lenvatinib in blood plasma. From each participant, a total of up to 12 blood samples were collected at the following specified time points: predose, 0.5 to 4 hours postdose, and 6 to 10 hours postdose on Cycle 1/Day 1 and Cycle 1/Day 15; predose and 2 to 12 hours postdose on Cycle 2/Day 1; and predose only on Day 1 of Cycles 3 to 6. The samples were analyzed for the concentration of lenvatinib using validated analytical methods. Population PK model and observed concentration data were used to derive model-predicted lenvatinib PK parameters and lenvatinib exposure (AUC) based on the 24 mg starting dose.</description>
          <population>PK Analysis Set - All the subjects who received at least one dose of study drug and had evaluable PK data</population>
          <units>ng*h/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3490" lower_limit="1410" upper_limit="10700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For each participant, from the first dose till 30 days after the last dose or the cut-off date for the primary analysis whichever was earlier or up to approximately 2.5 years</time_frame>
      <desc>Safety was assessed by the monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs); regular monitoring of hematology, clinical chemistry, and urine values; physical examinations; and regular measurement of vital signs, electrocardiograms (ECG), and echocardiograms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lenvatinib (Randomization Phase)</title>
          <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Randomization Phase)</title>
          <description>Participants received blinded study drug (lenvatinib 24 mg/placebo, orally once daily) in 2:1 ratio until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="E3">
          <title>Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)</title>
          <description>Placebo treated participants in the Randomization Phase who had progressive disease confirmed by IIR, and who requested treatment with lenvatinib</description>
        </group>
        <group group_id="E4">
          <title>Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)</title>
          <description>Placebo treated participants in the Randomization Phase who had progressive disease confirmed by IIR, and who requested treatment with lenvatinib. The starting dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The starting dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Right ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Radicular cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gallbladder mucocoele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Testicular abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diabetic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Osmotic demyelination syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Postictal paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Laryngeal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Laryngeal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Laryngeal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pleural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Services</name_or_title>
      <organization>Eisai, Inc.</organization>
      <phone>1-888-422-4743</phone>
      <email>esi_medinfo@eisai.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

